PCVX vs. SMMT: Vaxcyte vs. Summit Therapeutics Stock Comparison
How do Vaxcyte (PCVX) and Summit Therapeutics (SMMT) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Vaxcyte (PCVX) and Summit Therapeutics (SMMT) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.
| Profile Item | PCVX | SMMT |
|---|---|---|
| Name | Vaxcyte Inc. | Summit Therapeutics Inc. |
| Country/Region | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Biotechnology |
| GICS Sub-Industry | Biotechnology | Biotechnology |
| Market Capitalization | 10.11 billion USD | 13.06 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | Nasdaq |
| Listing Date | June 12, 2020 | March 5, 2015 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | PCVX | SMMT |
|---|---|---|
| Total Return (1Y) | 59.00% | -2.48% |
| Total Return (3Y, Annualized) | 11.29% | 116.18% |
| Total Return (5Y, Annualized) | 21.60% | 26.89% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
Summit Therapeutics (SMMT) reports a negative beta of -1.51, suggesting inverse market sensitivity over the measurement window. That is uncommon for ordinary equities and can reflect commodity-linked or hedge-like exposure, but it can also come from statistical noise. Vaxcyte (PCVX) has a non-negative beta of 1.26.
| Metric | PCVX | SMMT |
|---|---|---|
| Volatility (1Y, Annualized) | 56.01% | 75.06% |
| Beta (5Y) | 1.26 | -1.51 |
| Max Drawdown (5Y) | -76.22% | -87.64% |
| Avg. Volume (3M) | 2.12M | 6.19M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | PCVX | SMMT |
|---|---|---|
| Sharpe Ratio (1Y) | 0.98 | -0.09 |
| Sortino Ratio (1Y) | 1.76 | -0.13 |
Profitability
ROE (TTM)
Both Vaxcyte (PCVX) at -42.68% and Summit Therapeutics (SMMT) at -220.01% report negative ROE values. Negative ROE can reflect losses or negative shareholders’ equity, so both readings need extra context.
PCVX
Pharmaceuticals, Biotechnology & Life Sciences industry group
-42.68%
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- PCVX
- -42.68%
- Q1
- -64.05%
- Min
- -167.77%
SMMT
Pharmaceuticals, Biotechnology & Life Sciences industry group
-220.01%
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
- SMMT
- -220.01%
Net Margin (TTM)
Both Vaxcyte (PCVX) at 0.00% and Summit Therapeutics (SMMT) at 0.00% keep about the typical share of revenue as profit for their industries — neither bottom line stands out from peers.
PCVX
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- Max
- 18.05%
- Q3
- 4.78%
- PCVX
- 0.00%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
SMMT
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- Max
- 18.05%
- Q3
- 4.78%
- SMMT
- 0.00%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Both Vaxcyte (PCVX) at 0.00% and Summit Therapeutics (SMMT) at 0.00% run core operations about as efficiently as their industries’ norm — neither stands out on operating profitability.
PCVX
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- Max
- 83.12%
- Q3
- 14.77%
- PCVX
- 0.00%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
SMMT
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- Max
- 83.12%
- Q3
- 14.77%
- SMMT
- 0.00%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | PCVX | SMMT |
|---|---|---|
| ROE (TTM) | -42.68% | -220.01% |
| ROA (TTM) | -24.98% | -111.99% |
| Net Margin (TTM) | 0.00% | 0.00% |
| Operating Margin (TTM) | 0.00% | 0.00% |
| Gross Margin (TTM) | 0.00% | 0.00% |
Growth
Revenue Growth
Neither Vaxcyte (PCVX) nor Summit Therapeutics (SMMT) reports a revenue growth value for this period, so a direct comparison isn't possible.
EPS Growth
Neither Vaxcyte (PCVX) nor Summit Therapeutics (SMMT) reports a EPS growth value for this period, so a direct comparison isn't possible.
Growth Metrics
| Metric | PCVX | SMMT |
|---|---|---|
| Revenue Growth (YoY) | -- | -- |
| Revenue Growth (3Y CAGR) | -- | -- |
| EPS Growth (YoY) | -- | -- |
| EPS Growth (3Y CAGR) | -- | -- |
Financial Strength
Current Ratio (MRQ)
Both Vaxcyte (PCVX) at 4.56 and Summit Therapeutics (SMMT) at 5.99 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.
PCVX
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.56
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- PCVX
- 4.56
- Q1
- 2.47
- Min
- 0.10
SMMT
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.99
- Max
- 25.13
- Q3
- 12.13
- SMMT
- 5.99
- Median
- 5.52
- Q1
- 2.47
- Min
- 0.10
Debt / Equity (MRQ)
Both Vaxcyte (PCVX) at 0.09 and Summit Therapeutics (SMMT) at 0.04 fund their balance sheets with roughly industry-typical debt-to-equity mixes.
PCVX
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.09
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- PCVX
- 0.09
- Q1
- 0.02
- Min
- 0.00
SMMT
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.04
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- SMMT
- 0.04
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | PCVX | SMMT |
|---|---|---|
| Current Ratio (MRQ) | 4.56 | 5.99 |
| Debt / Equity (MRQ) | 0.09 | 0.04 |
| Net Debt / EBITDA | -- | -- |
Dividends
Dividend Yield (TTM)
Neither Vaxcyte (PCVX) nor Summit Therapeutics (SMMT) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
PCVX
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- PCVX
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
SMMT
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- SMMT
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Neither Vaxcyte (PCVX) nor Summit Therapeutics (SMMT) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
PCVX
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- PCVX
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
SMMT
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- SMMT
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | PCVX | SMMT |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
P/E Ratio (TTM)
Neither Vaxcyte (PCVX) nor Summit Therapeutics (SMMT) reports a P/E ratio value for this period, so a direct comparison isn’t possible.
PCVX
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- PCVX
- --
SMMT
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- SMMT
- --
P/S Ratio (TTM)
Neither Vaxcyte (PCVX) nor Summit Therapeutics (SMMT) reports a P/S ratio value for this period, so a direct comparison isn’t possible.
PCVX
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
- PCVX
- --
SMMT
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
- SMMT
- --
P/B Ratio (MRQ)
Vaxcyte (PCVX) at 3.83 sits near its industry’s typical P/B ratio, while Summit Therapeutics (SMMT) at 23.13 prices above its benchmark range — SMMT looks rich relative to book.
PCVX
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.83
- Max
- 13.53
- Q3
- 6.54
- PCVX
- 3.83
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
SMMT
Pharmaceuticals, Biotechnology & Life Sciences industry group
23.13
- SMMT
- 23.13
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | PCVX | SMMT |
|---|---|---|
| P/E Ratio (TTM) | -- | -- |
| P/S Ratio (TTM) | -- | -- |
| P/B Ratio (MRQ) | 3.83 | 23.13 |
| Free Cash Flow Yield (TTM) | -5.24% | -1.64% |